Sprawozdanie z Advanced Breast Cancer Second International Consensus Conference
作者： Ewa Szombara , Katarzyna Pogoda , Renata Sienkiewicz-Kozłowska
DOI:
关键词:
摘要: The Advanced Breast Cancer Second International Consensus Conference (ABC2) was held on 7th–9th November 2013. current consensus guidelines for the management of locally advanced and metastatic breast cancer developed. In patients with therapy begins a systemic treatment, followed by surgery (generally radical mastectomy) adjuvant radiotherapy, even in who achieved complete pathological response. Adjuvant hormonal is used hormone-dependent cancer. validity early assessment effectiveness highlighted. Evaluation responseis recommended after two courses chemotherapy further treatment should be guided depending role anti-HER2 targeted HER2-positive emphasized. Benefits liver metastasis before metastasectomy, pleural effusion thoracocentesis pleurodesis, brain local locoregional recurrence were stressed.
参考文章(26)
S. Dawood, S.D. Merajver, P. Viens, P.B. Vermeulen, S.M. Swain, T.A. Buchholz, L.Y. Dirix, P.H. Levine, A. Lucci, S. Krishnamurthy, F.M. Robertson, W.A. Woodward, W.T. Yang, N.T. Ueno, M. Cristofanilli, International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment Annals of Oncology. ,vol. 22, pp. 515- 523 ,(2011) , 10.1093/ANNONC/MDQ345
Thomas Bachelot, Céline Bourgier, Claire Cropet, Isabelle Ray-Coquard, Jean-Marc Ferrero, Gilles Freyer, Sophie Abadie-Lacourtoisie, Jean-Christophe Eymard, Marc Debled, Dominique Spaëth, Eric Legouffe, Djelila Allouache, Claude El Kouri, Eric Pujade-Lauraine, Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study Journal of Clinical Oncology. ,vol. 30, pp. 2718- 2724 ,(2012) , 10.1200/JCO.2011.39.0708
Sandra M Swain, Sung-Bae Kim, Javier Cortés, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Adam Knott, Emma Clark, Graham Ross, Mark C Benyunes, José Baselga, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncology. ,vol. 14, pp. 461- 471 ,(2013) , 10.1016/S1470-2045(13)70130-X
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Vladimir Semiglazov, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncology. ,vol. 13, pp. 25- 32 ,(2012) , 10.1016/S1470-2045(11)70336-9
Gunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, Peter A. Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, Jörn Hilfrich, Holger Eidtmann, Bernd Gerber, Claus Hanusch, Thorsten Kühn, Andreas du Bois, Jens-Uwe Blohmer, Christoph Thomssen, Serban Dan Costa, Christian Jackisch, Manfred Kaufmann, Keyur Mehta, Michael Untch, Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study Journal of Clinical Oncology. ,vol. 28, pp. 2015- 2023 ,(2010) , 10.1200/JCO.2009.23.8303
Javier Cortes, Joyce O'Shaughnessy, David Loesch, Joanne L Blum, Linda T Vahdat, Katarina Petrakova, Philippe Chollet, Alexey Manikas, Veronique Diéras, Thierry Delozier, Vladimir Vladimirov, Fatima Cardoso, Han Koh, Philippe Bougnoux, Corina E Dutcus, Seth Seegobin, Denis Mir, Nicole Meneses, Jantien Wanders, Chris Twelves, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study The Lancet. ,vol. 377, pp. 914- 923 ,(2011) , 10.1016/S0140-6736(11)60070-6
Brian D. Lehmann, Joshua A. Bauer, Xi Chen, Melinda E. Sanders, A. Bapsi Chakravarthy, Yu Shyr, Jennifer A. Pietenpol, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies Journal of Clinical Investigation. ,vol. 121, pp. 2750- 2767 ,(2011) , 10.1172/JCI45014
G.A.M. van Walsum, J.A.M. de Ridder, C. Verhoef, K. Bosscha, T.M. van Gulik, E.J. Hesselink, T.J.M. Ruers, M.P. van den Tol, I.D. Nagtegaal, M. Brouwers, R. van Hillegersberg, R.J. Porte, A.M. Rijken, L.J.A. Strobbe, J.H.W. de Wilt, Resection of liver metastases in patients with breast cancer: Survival and prognostic factors Ejso. ,vol. 38, pp. 910- 917 ,(2012) , 10.1016/J.EJSO.2012.04.015
Stephen RD Johnston, Lucy S Kilburn, Paul Ellis, David Dodwell, David Cameron, Larry Hayward, Young-Hyuck Im, Jeremy P Braybrooke, A Murray Brunt, Kwok-Leung Cheung, Rema Jyothirmayi, Anne Robinson, Andrew M Wardley, Duncan Wheatley, Anthony Howell, Gill Coombes, Nicole Sergenson, Hui-Jung Sin, Elizabeth Folkerd, Mitch Dowsett, Judith M Bliss, SoFEA Investigators, Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncology. ,vol. 14, pp. 989- 998 ,(2013) , 10.1016/S1470-2045(13)70322-X
Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino, Liang Fang, Michael W. Lu, Steven Olsen, Kim Blackwell, Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer The New England Journal of Medicine. ,vol. 367, pp. 1783- 1791 ,(2012) , 10.1056/NEJMOA1209124